

LAHIVE  
&  
COCKFIELD  
LLP

COUNSELLORS AT LAW  
28 STATE STREET  
BOSTON, MASSACHUSETTS 02109-4784  
TELEPHONE (617) 227-7400  
FAX (617) 742-4214  
le@lahive.com

JOHN A. LAHIVE JR. (1928-1997)  
THOMAS V. SMURZYNSKI  
RALPH A. LOREN  
GIULIO A. DeCONTI JR.  
ANN LAMPORT HAMMITTE  
ELIZABETH A. HANLEY  
AMY BAKER MANDRAGOURAS  
ANTHONY A. LAURENTANO  
KEVIN J. CANNING  
JANE E. REMILLARD  
DEANN FORAN SMITH  
PETER C. LAURO  
JEANNE M. DIGIORGIO  
DEBRA J. MILASINIC Ph.D.  
DAVID J. RIKKERS  
DAVID R. BURNS  
JOHN S. CURRAN  
SEAN D. DETWEILER

CYNTHIA L. KANIK Ph.D.  
MEGAN E. WILLIAMS Ph.D.  
RICHANAND  
MICHAEL PHILLIPPS  
LISA M. DIROCCO  
HATHAWAY P. RUSSELL \*\*\*

SENIOR COUNSEL  
JAMES E. COCKFIELD

OF COUNSEL  
JEREMIAH LYNCH  
WILLIAM A. SCOFIELD JR.

PATENT AGENTS  
THEODORE R. WEST  
SHAYNE Y. HUFF Ph.D.  
DANIEL B. KO

TECHNICAL SPECIALISTS

MARIA LACCOTRIPE ZACHARAKIS Ph.D. \*\*  
CYNTHIA M. SOROOS  
PETER W. DINI Ph.D.  
EUIHOON LEE  
JENNIFER K. ROSENFELD  
ALLAN TAMESHTIT Ph.D.  
CATHERINE E. McPHERSON  
ERIC F. WAGNER Ph.D.  
SHAHID HASAN Ph.D.  
JACOB G. WEINTRAUB  
PETER A. DIMATTIA  
JONATHAN M. SPARKS Ph.D.  
CRISTIN E. HOWLEY Ph.D.  
VINCENT P. LOCCISANO  
MERIDETH C. ARNOLD

\* Admitted in NY only  
\*\* Passed the Patent Bar Examination  
\*\*\* Admitted in TX only

December 28, 2001

Commissioner for Patents  
Box Sequence  
Washington, D.C. 20231

RECEIVED

FEB 04 2002

TECH CENTER 1600/2930

Re: U.S. Continuation-in-Part Patent Application Serial No. 09/847,940  
Title: "Anti-Inflammatory Compounds and Uses Thereof"  
Inventors: Michael J. May and Sankar Ghosh  
Filing Date: May 2, 2001  
Attorney Docket No. PPI-117CP

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. Preliminary Amendment and Response to Notice to Comply With Sequence Listing Requirements (2 pgs);
2. Transmittal Letter for Diskette Containing Sequence Listing (1 pg);
3. 6 pages of Sequence Listing (Paper Copy);
4. Diskette Containing Computer Readable Copy of Sequence Listing;
5. Statement of Limited Recognition Under 37 C.F.R. §10.9(b);
6. Copy of Notice to Comply with Sequence Listing Requirements (Formalities Letter); and
7. Pre-paid acknowledgment postcard.

Please charge any necessary fees to our Deposit Account No. 12-0080. The undersigned requests any extensions of time necessary to respond. *For this purpose, a duplicate of this sheet is enclosed.*

**Certificate of First Class Mailing (37 CFR 1.8(a))**

I hereby certify that this transmittal letter and the papers referred to as being enclosed therein are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Box Sequence, Washington, DC 20231 on:

December 28, 2001

Date


Maria C. Laccotripe  
Limited Recognition Under 37 C.F.R. § 10.9(b)

LAHIVE & COCKFIELD, LLP

Attorneys at Law

By:

Maria C. Laccotripe, Ph.D., J.D.  
Limited Recognition Under 37 C.F.R. §10.9(b)  
Agent for Applicant



UNITED STATES PATENT AND TRADEMARK OFFICE


COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 2023  
WWW.USPTO.GOV

APPLICATION NUMBER	APPLICATION DATE	EXAMINER NAME	ATTORNEY REFERENCE
09 847,940	05 02 2001	Michael J. May	PPI-117CP

000959  
LAHIVE & COCKFIELD  
28 STATE STREET  
BOSTON, MA 02109

CONFIRMATION NO. 6156

## FORMALITIES LETTER



\*OC000000007142183\*

Date Mailed: 11/30/2001

### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice MUST be returned with the reply.*

Customer Service Center  
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE